Neurological manifestations of HIV-1 infection

Enting, R.H.

Citation for published version (APA):
Enting, R. H. (2000). Neurological manifestations of HIV-1 infection
Lymphomatous meningitis in AIDS-related systemic non-Hodgkin's lymphoma
A report of eight cases

Roelien H Enting, Rianne AJ Esselink, Peter Portegies

Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands

Abstract

Meningeal involvement occurred in 8 (22%) of 36 adult patients with AIDS-related systemic non-Hodgkin's lymphoma, seen in a ten-year-period. Clinical symptoms consisted of cranial nerve palsies, radicular involvement, headache or diffuse encephalopathy. Cerebrospinal fluid examination established the diagnosis in all cases. Systemic disease had been diagnosed 7-33 weeks prior to lymphomatous meningitis in 6 patients, whereas in the remaining two patients diagnoses of systemic and meningeal disease were made simultaneously. All patients had intermediate or high grade lymphomas and widespread disease. By contrast with non-AIDS related lymphomas, bone marrow involvement at initial staging cannot be used to select patients for prophylactic treatment, as 7 out of our 8 patients had no initial bone marrow involvement. In this retrospective review, prognosis of lymphomatous meningitis was extremely poor, with a mean survival of only 5 weeks. Survival of patients with systemic lymphoma who eventually developed lymphomatous meningitis was 4.0 months compared to 7.2 months for those who did not. In our experience, lymphomatous meningitis has the worst outcome of all AIDS-related neurological complications, regardless of treatment.
INTRODUCTION

The acquired immune deficiency syndrome (AIDS) is associated with an increased incidence of non-Hodgkin's lymphoma. These lymphoma's are usually systemic high-grade B-cell-lymphomas (immunoblastic lymphoma, Burkitt's lymphoma) and primary lymphoma of the brain. Systemic high grade lymphomas have been reported in 2.3% of cases of AIDS, compared with a prevalence of 0.05% in the general population. In non-AIDS-related systemic lymphomas central nervous system involvement is not a frequent complication and occurs almost exclusively in intermediate and high grade malignancies (according to the Working Formulation). Meningeal involvement has been found in 2-8%, cerebral in 1-2.5%, and epidural in 0.5-6%.

Meningeal involvement occurs far more frequently in AIDS-related systemic lymphomas and has been reported in 12-26% at the initial presentation. Data on meningeal relapse after treatment are sparse.

We have reviewed the records of all patients with HIV-related neurological complications examined at the Academic Medical Center in Amsterdam in the period of September 1982 to September 1992. We report the clinical findings, course, treatment and histopathologic findings of eight patients with AIDS-related systemic non-Hodgkin's lymphoma and meningeal involvement.

PATIENTS AND METHODS

From a review of the medical records of all HIV-infected patients seen for neurological complications (n=635) in the period of September 1982 to September 1992 we identified eight cases of lymphomatous meningitis in AIDS-related systemic non-Hodgkin's lymphoma. Prevalence of this neurologic complication is 1.2% among all neurologic complications. In order to find all cases of AIDS-related systemic non-Hodgkin's lymphoma during this period a computerized search was performed of the combined discharge diagnoses of HIV-infection/AIDS and non-Hodgkin's lymphoma. This search yielded 36 patients. We eventually reviewed the medical records of these patients for survival data. Examination of the spinal fluid has not been part of the routine staging procedures until September 1992. Neurological and spinal fluid examination in these 36 patients were performed when neurological abnormalities were present. Clinical evaluation included age, sex, AIDS risk factors, prior AIDS-related complications, CD4-positive lymphocyte counts (CD4 count), clinical stage at presentation (Ann Arbor stage I-IV (stage I: involvement of a single lymph node region or of a single parenchymal organ; stage IV: disseminated foci of one or more parenchymal organs with or without lymph node involvement or a single lesion in liver or bone marrow; the presence of fever, night sweats or weight loss is denoted by the suffix letter B), histology (Working Formulation and Kiel classification), treatment regimens, response to initial systemic therapy, time course to development of meningeal involvement, signs and symptoms of meningeal involvement, spinal fluid findings, radiologic findings, therapy and survival from the

Leptomeningeal metastasis of HIV-related systemic NHL
date of the diagnostic procedure. Autopsy was performed in four patients.

**RESULTS**

Thirty-six patients with systemic non-Hodgkin’s lymphoma and AIDS were seen in the Academic Medical Centre of Amsterdam in a 10-year period. Meningeal involvement occurred in eight (22%) of all patients with systemic lymphoma. Two patients had lymphomatous meningitis at the initial presentation of systemic lymphoma and six developed lymphomatous meningitis.

Seven male patients and one female patient had a mean age of 38 years (range 29-57 years). Five men were homosexual, one was an intravenous drug abuser and two patients probably had been infected by heterosexual contacts. An AIDS-diagnosing event had preceded the onset of systemic lymphoma in three patients; one patient had been diagnosed with *Pneumocystis carinii* pneumonia and *Candida* oesophagitis, the second patient with Kaposi’s sarcoma, and the third with *Candida* oesophagitis. The mean CD4 count at the time of diagnosis of systemic disease was 0.2x10⁹/l (range 0.01-0.66x10⁹/l) (normal: 0.5-1.57x10⁹/l) (see Table).

Systemic non-Hodgkin’s lymphoma had been diagnosed in all patients before or simultaneously with meningeal involvement. Histologic examination revealed B-cell lymphomas in seven patients; in one patient a B-cell origin could not be proved. Six patients had high grade lymphoma (according to the Working Formulation), three of them had Burkitt’s lymphoma, two of them immunoblastic lymphoma and one lymphoblastic lymphoma. The other two patients had at least intermediate grade lymphoma, one of them had a mixed immunoblastic/centroblastic lymphoma, the other one had a centroblastic lymphoma. We did not find any case of low grade lymphoma with meningeal involvement.

Clinical staging using the Ann Arbor classification was performed in all patients; seven patients had stage IVb disease and one patient had stage Ib disease. All patients underwent bone marrow biopsy for staging procedures, only one patient had bone marrow infiltration. The general condition was good in four patients, fair in three and poor in one.

Six patients in whom systemic lymphoma had been found before meningeal involvement occurred were treated with two to four CNOP (cyclophosphamide, mitoxantrone, vincristine, prednisone) regimens. One had progressive lymphoma and treatment was switched to DAP (dexamethasone, cytarabine, cisplatin) regimens. In four patients (1,2,4,6) antiretroviral medication was discontinued during chemotherapy, in the remaining four patients zidovudine was never started. One patient had a complete remission (2), another had a partial remission (5), and four had progressive disease. The mean interval between the diagnosis of systemic lymphoma and meningeal infiltration was 13 weeks (range 0-33 weeks). The CD4 counts had by then decreased to a mean value of 0.15x10⁹/l.

Six patients presented with a cranial nerve palsy, in three of them multiple cranial nerves were involved (the abducens nerve was five times involved). One patient presented with spinal root dysfunction. One patient had a diffuse
Table
Characteristics of eight patients with lymphomatous meningitis and AIDS

<table>
<thead>
<tr>
<th>Patients</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>male</td>
<td>male</td>
<td>female</td>
<td>male</td>
<td>male</td>
<td>male</td>
<td>male</td>
<td>male</td>
</tr>
<tr>
<td>Age (years)</td>
<td>57</td>
<td>30</td>
<td>49</td>
<td>29</td>
<td>30</td>
<td>30</td>
<td>46</td>
<td>32</td>
</tr>
<tr>
<td>Risk group</td>
<td>homo-</td>
<td>homo-</td>
<td>-</td>
<td>-</td>
<td>homo-</td>
<td>IV drugs</td>
<td>homo-</td>
<td>homo-</td>
</tr>
<tr>
<td>sexual</td>
<td>sexual</td>
<td></td>
<td></td>
<td></td>
<td>sexual</td>
<td></td>
<td>sexual</td>
<td>sexual</td>
</tr>
<tr>
<td>Histology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kiel Classification</td>
<td>IB</td>
<td>B</td>
<td>B</td>
<td>CBIB</td>
<td>LB</td>
<td>IB</td>
<td>CB</td>
<td>B</td>
</tr>
<tr>
<td>Working Formulation</td>
<td>HG</td>
<td>HG</td>
<td>HG</td>
<td>IG or HG</td>
<td>HG</td>
<td>HG</td>
<td>IG or HG</td>
<td>HG</td>
</tr>
<tr>
<td>Stage (Ann Arbor)</td>
<td>IV b</td>
<td>IV b</td>
<td>IV b</td>
<td>IV b</td>
<td>IV b</td>
<td>IV b</td>
<td>IV b</td>
<td>IV b</td>
</tr>
<tr>
<td>CD4 cell count while systemic NHL</td>
<td>100</td>
<td>30</td>
<td>140</td>
<td>80</td>
<td>230</td>
<td>400</td>
<td>10</td>
<td>660</td>
</tr>
<tr>
<td>CDC classification</td>
<td>III</td>
<td>IV A</td>
<td>III</td>
<td>IV C1</td>
<td>III</td>
<td>IV C1</td>
<td>IV D</td>
<td>III</td>
</tr>
<tr>
<td>Bone marrow infiltration</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>Time to meningitis (weeks)</td>
<td>21</td>
<td>14</td>
<td>7</td>
<td>15</td>
<td>33</td>
<td>0</td>
<td>13</td>
<td>0</td>
</tr>
<tr>
<td>CD4 count while LM</td>
<td>30</td>
<td>50</td>
<td>10</td>
<td>60</td>
<td>30</td>
<td>10</td>
<td>10</td>
<td>id</td>
</tr>
<tr>
<td>Therapy</td>
<td>MTX 6x</td>
<td>MTX 8x</td>
<td>MTX 8x</td>
<td>MTX 5x</td>
<td>MTX 7x</td>
<td>-</td>
<td>MTX 1x</td>
<td>RTX</td>
</tr>
<tr>
<td>Survival</td>
<td>11 days</td>
<td>4 weeks</td>
<td>5 weeks</td>
<td>8 weeks</td>
<td>4 weeks</td>
<td>14 weeks</td>
<td>5 days</td>
<td>2 weeks</td>
</tr>
</tbody>
</table>

Kiel Classification: IB = immunoblastic lymphoma; B = Burkitt's lymphoma; CBIB = lymphoblastic lymphoma; CB = centroblastic lymphoma;
Working Formulation: HG = high grade; IG = intermediate grade;
LM = lymphomatous meningitis; MTX = methotrexate; RTX = radiotherapy
CD4 cell counts are given per μl
encephalopathy only. Accompanying symptoms in the other 7 patients consisted of headache, nausea, vomiting and/or diffuse encephalopathy. The general condition often had deteriorated; the clinical condition was good in 1 patient, fair in three and poor in four patients.

Metastatic meningeal involvement was found by CSF examination in all patients. In seven patients the first lumbar puncture revealed pathologic cells. One patient had manifested an abducens palsy 5 months prior to proven meningeal involvement. CSF examination had been performed five times, but no malignant cells were found. He eventually developed multiple cranial nerve palsies; reexamination of spinal fluid then revealed lymphoma cells. No further specific abnormalities of the spinal fluid were found; a slight to severe pleiocytosis was always present (range 6-250 leukocytes per mm$^3$), protein content was elevated in four patients (mean 0.7 g/l, range 0.16-1.51 g/l), hypoglycorrhagia was found in three patients.

CT scanning of the brain before and after administration of iodinated contrast was performed in all patients. In four patients no abnormalities were found, in the other four patients only mild atrophy was found.

All our patients did poorly, either with or without treatment. The average survival was only five weeks (range 5 days-14 weeks). The mean survival of these patients from the date of diagnosis of systemic disease was 4.0 months (95% confidence interval: 2.1-5.9 months). Two patients (1,7) with progressive systemic disease and poor clinical condition refused treatment. They died 5 and 11 days after the diagnostic procedure.

Treatment data are available in six patients. Five patients (2-6) had an Ommaya reservoir implanted and were treated with intraventricular methotrexate. One patient (5) received additional irradiation on the base of the skull. Two of the five patients (2,6) had a short-lived (one to two weeks) and slight clinical improvement. Two patients (4,5) had a short-lived (one to three weeks) stabilization of neurologic symptoms. One patient developed progressive disease, consisting of hemiparesis and hemihypesthesia (3). One patient (8) was treated with intrathecal methotrexate and steroids once and he started with whole brain radiation, but neurological signs and symptoms progressed and treatment was discontinued. No lymphoma cells could be detected in the CSF of four patients (2,3,4,6) after a mean duration of treatment of ten days, but in two patients (4,6) pathologic cells recurred. In two patients (5,8) pathologic cells remained present.

Systemic chemotherapy was continued in 3 patients (3,4,5) and was started in two patients (6,8). In the sixth patient (2) systemic treatment was not re instituted; a systemic relapse was not present. Two (3,6) received CNOP regimens, two (4,5) received DAP regimens and one patient (8) received vincristine only. In four patients treatment eventually had to be discontinued because of progressive (5,8) or recurrent (4,6) lymphomatous meningitis, all of whom also had progressive systemic disease. In one patient cerebrospinal fluid turned tumor-negative, but neurologic symptoms progressed, and she died of progressive systemic and
meningeal disease (3). In the sixth patient cerebrospinal fluid also turned negative, but he died of a status epilepticus (2). At autopsy he showed no systemic or meningeal disease.

In order to compare the mean survival of the patients who developed lymphomatous meningitis to the survival of those who did not, we calculated the duration of survival (in months) from the diagnostic procedure to the date of death in 28 patients without meningeal involvement. We excluded three patients in whom the diagnosis has been made recently. We found a mean duration of survival of 7.2 months (95% confidence interval: 3.8-10.6 months) for 25 patients. No significant difference in survival could be found between patients with meningeal involvement and those without.

Autopsy findings were available in four patients (1,2,5,6). Three of them (1,5,6) had evidence of multifocal systemic lymphoma. One untreated patient (1) showed leptomeningeal involvement and tumour cells in Virchow-Robin spaces. In one treated patient (2) no evidence of metastatic lymphoma could be found. One treated patient (6) had both leptomeningeal involvement and intracerebral metastases in the brainstem, another treated patient (5) showed leptomeningeal involvement.

**DISCUSSION**

When systemic non-Hodgkin's lymphoma occurs, it often is an early complication of HIV-infection; no prior AIDS-defining diagnoses had occurred in 55% (range between reports 32-77%) of cases. The overall median survival of AIDS patients with systemic intermediate or high grade non-Hodgkin's lymphoma is 4-7 months; factors predictive of survival differ among reports and include histologic subtype, initial staging, bone marrow involvement, prior AIDS diagnosis, CD4 counts, Karnofski performance status, treatment regimen and response to treatment. About half of them achieves complete remission following treatment, but relapses are frequent. The cause of death is either progressive lymphoma or opportunistic infection or both.

In non-AIDS patients risk factors for meningeal involvement include aggressive histopathologic subtype, stage IV disease, and bone marrow involvement at initial presentation.

Patients with AIDS often have aggressive and widespread systemic lymphoma. Bone marrow involvement at initial staging cannot be used to select patients who may be at high risk for lymphomatous meningitis. This association is not uniformly found in patients with AIDS.

The clinical presentation of meningeal involvement in our patients corresponds well with previous reports. The prognosis of lymphomatous meningitis is extremely poor. In our population mean survival was only five weeks. Survival was shortest in those patients who received no treatment at all; in both patients treatment was not initiated because of a poor condition and the presence of progressive systemic disease. However, the marginally longer survival in our six treated patients consisted of
a period of hospitalization with at most a short-lived and slight clinical improvement.

No significant decrease in survival could be found in patients who eventually developed lymphomatous meningitis, compared to those who did not, but numbers are small. In order to improve survival, prevention of meningeal relapse in patients with a fair or good prognosis of systemic disease may be important. A recent prospective trial in AIDS patients who all underwent a lumbar puncture for staging showed that the combination of a less aggressive systemic chemotherapeutic schedule, prophylactic intrathecal treatment, an appropriate antiretroviral medication and prophylactic treatment of opportunistic infections seems promising. No meningeal relapses were seen in those patients who had a partial or complete remission (51% of all patients) after treatment. Nevertheless, median survival in this series (6.5 months) did not differ much from that found in the above-mentioned retrospective series.\textsuperscript{1,8,9,13-15}

Lymphomatous meningitis frequently occurs in AIDS-related systemic non-Hodgkin's lymphoma. It still is a rare neurologic complication of AIDS, but the incidence has risen in recent years. Among all neurologic complications, lymphomatous meningitis has the bleakest outcome, with a mean survival of only five weeks, and no patient surviving more than 14 weeks in our population. Our experience seems to justify every trial with the intention of preventing this complication in systemic lymphoma.

The authors would like to express their appreciation to Mr. P. van Halem of the Office of Medical Registration for providing data on prevalence of systemic non-Hodgkin's lymphoma at the Academic Medical Center of Amsterdam from 1982-present and to Professor M. de Visser for critical comments.

\textbf{References}
